home
•
contacts
•
sitemap
•
japan
•
search
About
Company Overview
History
Management Team
Board of Directors
Locations
Careers
Pipeline
BTG Pipeline
Partnered Programmes
Marketed Products
Business Development
Our Focus
Partnering Opportunities
Contacts
Investors
Share Price Data
Stock Exchange Announcements
Press Releases
Financial Reports & Accounts
Financial Results
Presentations
BTG Share Dealing Facility
Email Alerts
Financial Calendar
Corporate Governance
Corporate Social Responsibility
Investor Contacts
News
Press Releases
Stock Exchange Announcements
Events
Publications
Email Alerts
Media Contact
Pipeline
BTG Pipeline
Varisolve
®
BGC20-0582
BGC20-0166
BGC20-1259
BGC20-1531
BGC20-0134
BTG6001
BTG6228
Partnered Programmes
Campath
®
CB7630 (abiraterone)
Misopess™
TRX4
Symadex
®
AQ4N
ABIO-0801
Juvidex™
Modafinil Combination
β-Amyloid Inhibitors
Marketed Products
Key
Neuroscience
Other
Pipeline
>
Partnered Programmes
Partnered Programmes
In addition to its growing pipeline of clinical and preclinical
development programmes
, BTG has assets in development with its licensees.
Campath
®
(Genzyme Corporation)
Multiple Sclerosis (MS)
CB7630 (abiraterone)
(Cougar Biotechnology, Inc)
Prostate cancer
Misopess
™
(Cytokine PharmaSciences)
Cervical ripening
TRX4
(Tolerx, Inc)
Type 1 diabetes, psoriasis
Symadex
®
(Xanthus Pharmaceuticals, Inc)
Metastatic breast cancer, MS
AQ4N
(Novacea, Inc)
Solid tumours
ABIO-0801
(Abiogen Pharma)
Anxiety
Juvidex
™
(Renovo Group plc)
Scar improvement
Modafinil Combination
(Victory Pharma)
Opiate-induced sleepiness
β-Amyloid Inhibitors
(Senexis)
Alzheimer's disease
© BTG International Ltd 2008 •
Legal Notice
•
Accessibility